ReviewInternational journal of clinical oncology2011
Proteomic analysis of soft tissue sarcoma.
Review in International journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?Clinical & experimental metastasis · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas are a heterogeneous group of malignant mesenchymal tumors, and novel tumors biomarkers and therapeutic targets are required to achieve early diagnosis and optimize therapy for individual patients. Global protein expression studies, an approach known as "proteomics", can offer important clues for understanding tumor biology that cannot be obtained by other approaches. Proteomic studies, such as two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry, have provided protein expression profiles of soft tissue tumors that can be used to develop novel diagnostic and therapeutic biomarkers and allow molecular classification of tumors. In this article, a brief description of the methodology will be provided, followed by a few examples of the recent proteomic studies that have generated new information for the diagnosis, classification and treatment of soft tissue tumors.
Indexed as
Identifiers
21384281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.